Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 5/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 6/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.51 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | CFTR | P13569 | 2/20 | 0.40 |
| ▸ | GHSR | Q92847 | 6/20 | 0.39 |
| ▸ | SMO | Q99835 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2629154 | 1.00 | CYP2C9 (0.57) | CYP2C9CYP2D6CYP3A4CYP2C19CYP1A2 | |
| SCHEMBL1763499 | 0.94 | CYP2D6 (0.63) | CYP2C9CYP2D6CYP3A4CYP2C19CYP1A2 | |
| SCHEMBL2629150 | 0.93 | CYP2C9 (0.57) | CYP2C9CYP2D6CYP3A4CYP2C19CYP1A2 | |
| SCHEMBL2633382 | 0.93 | CYP2C9 (0.57) | CYP2C9CYP2D6CYP3A4CYP2C19CYP1A2 | |
| SCHEMBL2629149 | 0.91 | CYP2D6 (0.48) | CYP2C9CYP2D6CYP3A4CYP2C19CYP1A2 | |
| SCHEMBL10292081 | 0.91 | CYP2D6 (0.48) | CYP2C9CYP2D6CYP3A4CYP2C19CYP1A2 | |
| SCHEMBL1763207 | 0.89 | CYP2C9 (0.72) | CYP2C9CYP2D6CYP3A4CYP2C19CYP1A2 | |
| SCHEMBL2633345 | 0.85 | CYP2C9 (0.63) | CYP2C9CYP2D6CYP3A4CYP2C19CYP1A2 | |
| SCHEMBL2628971 | 0.85 | CYP2C9 (0.63) | CYP2C9CYP2D6CYP3A4CYP2C19CYP1A2 | |
| SCHEMBL2633329 | 0.85 | CYP2C9 (0.63) | CYP2C9CYP2D6CYP3A4CYP2C19CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120238583-A1 | PHARMACEUTICAL FORMULATIONS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES WITH PROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-09-20 | — | — | US | disclosed |
| US-20120095017-A1 | PHARMACEUTICAL FORMULATIONS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES WITH PROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-04-19 | — | — | US | disclosed |
| US-20110118279-A1 | PHARMACEUTICAL FORMULATIONS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES WITH PROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-05-19 | — | — | US | disclosed |
| US-7662823-B2 | Pharmaceutical formulations of substituted azaindoleoxoacetic piperazine derivatives | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-02-16 | — | — | US | disclosed |
| US-7501420-B2 | Composition and antiviral of substituted azaindoleoxoacetic piperazine derivatives | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-03-10 | — | — | US | disclosed |
| US-20080119480-A1 | COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY | 2008-05-22 | — | — | US | disclosed |
| US-7354924-B2 | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238583-A1 | PHARMACEUTICAL FORMULATIONS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES WITH PROTEASE INHIBITORS | PREP, PEPD, DNPEP | CYP2C9 1267/4885CYP2D6 600/4885CYP3A4 224/4885 |
| US-20080119480-A1 | COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | ITPA, IDO1, IDO2 | CYP2C9 2812/4885CYP2D6 943/4885CYP3A4 494/4885 |
| US-20120095017-A1 | PHARMACEUTICAL FORMULATIONS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES WITH PROTEASE INHIBITORS | PREP, PEPD, DNPEP | CYP2C9 1267/4885CYP2D6 600/4885CYP3A4 224/4885 |
| US-20110118279-A1 | PHARMACEUTICAL FORMULATIONS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES WITH PROTEASE INHIBITORS | PREP, PEPD, DNPEP | CYP2C9 1267/4885CYP2D6 600/4885CYP3A4 224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.